BioMedNewsBreaks

ThursdayFeb 04, 2021 9:16 am

BioMedNewsBreaks – Capricor Therapeutics Inc. (NASDAQ: CAPR) Featured by M-Vest

Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, was recently highlighted as a featured company by M-Vest. The business description reads, “CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 200 human subjects across several clinical trials.” For more details, visit https://ibn.fm/Ejtce About Capricor Therapeutics Inc. Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization…

Continue Reading

TuesdayFeb 02, 2021 1:44 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. Litchfield Hills Research strictly follows FINRA standards for quality and objectivity, and the research firm has certified that the publication is compliant with FINRA research rules 2241, 3110. In addition, Litchfield confirmed that the report has been reviewed by a supervisory senior analyst and is…

Continue Reading

TuesdayFeb 02, 2021 10:49 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Trio of Upcoming Investment, Industry Events

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, is involved in several upcoming investment and industry conferences, and has released information regarding three upcoming investment and industry conferences in which it will be participating. The events include CSE Tech Tuesdays, a virtual public company showcase, which is today at 4:15 p.m. ET; World Agri-Tech Innovation Summit, a virtual innovation event slated for March 9–10; and the Banff Capital Conference, scheduled for March 12–14. The company noted that these events are part of MustGrow’s awareness initiatives. The…

Continue Reading

TuesdayFeb 02, 2021 10:38 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Marketing VP Authors Article on Increasing Need for Disposable Technologies

Brain Scientific (OTCQB: BRSF) vice president of marketing Stuart Bernstein has authored a DotMed Healthcare Business News article titled “COVID’s influence on neurology drives need for disposable technologies.” In the article, Bernstein notes both time management and infection control as key factors in the growing need for disposable technologies. The article states that headsets with pre-gelled and fixed electrodes could reduce the time-consuming electrode placement process. In addition, the article explains that commercially available EEG headsets that pair with encephalographs and amplifiers of EEG signals can deliver results in an average of 20 minutes. These time-saving measures mean that doctors could…

Continue Reading

TuesdayFeb 02, 2021 10:26 am

BioMedNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) to Postpone February Virtual Road Show

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and healthcare platform, has announced that it will postpone its upcoming virtual road show. Trxade had previously announced that the road show event would be held Wednesday, Feb. 3, 2021, at 11 a.m. ET. The company, which operates across the United States in all 50 states, will reschedule the event and announce the new date and time. Trxade Group is committed to its mission of making healthcare services affordable and accessible. “The virtual roadshow will be postponed to a later date, which will be announced via press release accompanied by a webcast link…

Continue Reading

MondayFeb 01, 2021 3:23 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, president and CEO of Genprex. “The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer (‘NSCLC’). Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso(R) for patients with late stage NSCLC whose disease progressed…

Continue Reading

MondayFeb 01, 2021 12:30 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Med-Tech Innovation Article

Brain Scientific (OTCQB: BRSF), a neurology focused device and software company, was featured in a recent Med-Tech Innovation article titled, “The need for neurological disposable tech amid the COVID-19 pandemic.” In the piece, Brain Scientific’s VP of Marketing, Stuart Bernstein, examines the need of neurological disposable technology following the effects of COVID0-19.  “The solution is clear and has come in the form of disposable EEG headsets,” Bernstein writes. “These devices can be quickly integrated into the current, standard medical processes for COVID-19 patients, and those without COVID-19, in need of a brain scan to swiftly acquire, record, transmit and display…

Continue Reading

FridayJan 29, 2021 3:08 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Across Continuum of Health Care

United Medical Equipment (“UME,” “UMEBSNI”) continues to address unique testing needs created by the ongoing global pandemic. As part of the company’s efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits that detect coronavirus antibodies that appear in the bloodstream of infected individuals within 10 minutes. The test can also indicate whether a person has protection against the coronavirus. In addition, UMEBSNI offers a unique mobile solution with testing specialists and experienced medical staff members providing onsite COVID-19 Rapid Testing and solutions to implement employee safety. These on-call mobile…

Continue Reading

FridayJan 29, 2021 2:40 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Promising Results from CyberAgrot Study

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, recently released potentially industry-changing results for its initial Colombia laboratory test. The study evaluated the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reported 100% control of the disease. A recent article discussing this reads, “In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated…

Continue Reading

ThursdayJan 28, 2021 2:04 pm

BioMedNewsBreaks – Clearside Biomedical Inc. (NASDAQ: CLSD) Closes Sale of Common Stock for $12M

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that it has closed the sale of 4,209,050 shares of common stock. The shares were priced at $2.851 per share, with the sale resulting in approximately $12 million. In the announcement, Clearside noted that the sale took place with institutional investors and certain existing stockholders. Clearside is recognized for its proprietary SCS Microinjector(R), designed to combat sight-threatening disease. The SCS Microinjector targets the suprachoroidal space (“SCS”) and provides access to the macula,…

Continue Reading